Company intelligence / Profile preview

GrapheneDx

Boston, Massachusetts, United Statesgraphenedx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GrapheneDx has developed a graphene-based biosensor platform with PCR-like sensitivity and the simplicity/cost-effectiveness of lateral flow tests. The first diagnostic applications target sexually transmitted infections using urine samples, aiming for results in less than 5 minutes. The technology supports multiplexing up to 32 analytes per test and requires no sample preparation. Clinical validation data are not yet public; products are still in development

Therapeutic areas: PulmonologyCardiovascularNeurologyInfectious Diseases
Modalities: DeviceBiosensor (Graphene field effect transistor-based)
Industry: Molecular Diagnostics

Partnerships

General Graphene Corporation (graphene material supply partner)Sapphiros (strategic commercialization/manufacturing partner)

Beyond the preview

Go deeper on GrapheneDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GrapheneDx.

Explore the full profile